2023 annual financial data
Inhibrx Biosciences 2023 Net margin
Direct answer
Net margin was -13,408.94%.
Operating income was -219,221,000 USD and net income was -241,361,000 USD.
Operating cash flow was -193,309,000 USD.
Get free Inhibrx Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,800,000 USD
- Operating income
- -219,221,000 USD
- Net income
- -241,361,000 USD
- Operating cash flow
- -193,309,000 USD